Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Oocyte Retrieval

Oocyte Retrieval

Oocyte Retrieval is the process of collecting mature oocytes (egg cells) from the ovaries, typically performed in assisted reproductive technologies such as in vitro fertilization (IVF).
This procedure involves the use of ultrasonography to guide a needle through the vaginal wall and into the ovarian follicles to aspirate the oocytes.
Oocyte Retrieval is a critical step in the IVF process, as the collected oocytes are then fertilized and the resulting embryos are transferred back to the patient's uterus in hopes of achieving a successful pregnancy.
Proper technique and optimization of Oocyte Retrival protocols are essential for maximizing the yield and quality of the collected oocytes, thereby enhancing the chances of a successful IVF outcome.
The PubCompare.ai platform can help researchers and clinicians identify the most effective Oocyte Retrival protocols through its advanced natural language processing and comprehensive analysis of published literature, preprints, and patents.

Most cited protocols related to «Oocyte Retrieval»

1
Comparative IVF Treatment Protocols
Cited 12 times
Clinical information from the subject’s electronic medical record was abstracted by the research nurses. All subjects underwent an evaluation for infertility which included a follicle-stimulating hormone (FSH) level drawn on the third day of the menstrual cycle to assess ovarian reserve. After completion of the standard infertility work-up, each subject was given an infertility diagnosis by their reproductive endocrinologist according to the Society for Assisted Reproductive Technology (SART) definitions. SART diagnoses consisted of male factor infertility which included poor semen quantity/quality; female factor infertility which included endometriosis, diminished ovarian reserve, tubal and uterine disorders; other causes and unexplained infertility.
Upon completion of the infertility evaluation, subjects underwent one of three IVF treatment protocols used at the MGH Fertility Center. The three IVF treatment protocols were: (1) Luteal phase GnRH-agonist protocol using low, regular and high-dose leuprolide (Lupron), in which pituitary desensitization was begun in the luteal phase; (2) Follicular phase GnRH-agonist/Flare protocol, in which Lupron was begun in the follicular phase on day 2 of menses at 20 units and decreased to the standard dose of five units on day 5; and (3) GnRH-antagonist protocol, in which GnRH-antagonist was begun when the lead follicle reached 14 mm in size. All cycles were preceded by a cycle of oral contraceptive pills unless contraindicated. On day 3 of induced menses, exogenous gonadotropins [FSH (Gonal-F, Follistim, Bravelle)] and/or Human Menopausal Gonadotropin [hMG (Repronex, Menopur)] were initiated. In the luteal phase GnRH-agonist protocol, Lupron dose was reduced at, or shortly after, the start of ovarian stimulation with FSH/hMG. FSH/hMG and GnRH-agonist or GnRH-antagonist was continued to the day of trigger with Human Chorionic Gonadotropin (hCG), 36 h before oocyte retrieval.
Mok-Lin E., Ehrlich S., Williams P.L., Petrozza J., Wright D.L., Calafat A.M., Ye X, & Hauser R. (2009). Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. International journal of andrology, 33(2), 385-393.
Publication 2009
Bravelle Contraceptives, Oral Diagnosis Endocrinologists Endometriosis Female Infertility Fertility Follistim Gonadorelin Gonadotropins Gonal F Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Hyposensitization Therapies Leuprolide Luteal Phase Male Infertility Menopur Menotropins Menstrual Cycle Menstrual Cycle, Proliferative Phase Menstruation Nurses Oocyte Retrieval Ovarian Follicle Ovarian Reserve Ovarian Stimulation Precipitating Factors Reproduction Repronex Semen Quality Sterility, Reproductive Treatment Protocols Uterine Diseases
2
Transplantation of GFP-expressing Mouse OSCs
Cited 9 times
GFP-expressing mouse OSCs (1 × 104) were injected directly into each ovary of wild-type mice at 2 months of age. Between 7–8 months of age, transplanted mice were subjected to an induced ovulation protocol. Cumulus-oocyte complexes were collected from the oviducts and assessed by direct fluorescence microscopy for GFP expression. For in-vitro fertilization (IVF), cumulus-oocyte complexes were mixed wild-type sperm for 4–5 h, washed and transferred to KSOM-AA medium (Irvine Scientific). Light and fluorescence microscopic examination was performed every 24 h for a total of 144 h to monitor embryo development48 (link). Ovarian tissue harvested at the time of oocyte collection was processed for immunohistochemical detection of GFP, as detailed46 (link).
White Y.A., Woods D.C., Takai Y., Ishihara O., Seki H, & Tilly J.L. (2012). Oocyte formation by mitotically-active germ cells purified from ovaries of reproductive age women. Nature medicine, 18(3), 413-421.
Publication 2012
Embryo Fertilization in Vitro Light Mice, Laboratory Microscopy, Fluorescence Oocyte Retrieval Oocytes Osteopathia striata cranial sclerosis Ovary Oviducts Ovulation Sperm Tissues
3
Transplantation of GFP-expressing Mouse OSCs
Cited 9 times
GFP-expressing mouse OSCs (1 × 104) were injected directly into each ovary of wild-type mice at 2 months of age. Between 7–8 months of age, transplanted mice were subjected to an induced ovulation protocol. Cumulus-oocyte complexes were collected from the oviducts and assessed by direct fluorescence microscopy for GFP expression. For in-vitro fertilization (IVF), cumulus-oocyte complexes were mixed wild-type sperm for 4–5 h, washed and transferred to KSOM-AA medium (Irvine Scientific). Light and fluorescence microscopic examination was performed every 24 h for a total of 144 h to monitor embryo development48 (link). Ovarian tissue harvested at the time of oocyte collection was processed for immunohistochemical detection of GFP, as detailed46 (link).
White Y.A., Woods D.C., Takai Y., Ishihara O., Seki H, & Tilly J.L. (2012). Oocyte formation by mitotically-active germ cells purified from ovaries of reproductive age women. Nature medicine, 18(3), 413-421.
Publication 2012
Embryo Fertilization in Vitro Light Mice, Laboratory Microscopy, Fluorescence Oocyte Retrieval Oocytes Osteopathia striata cranial sclerosis Ovary Oviducts Ovulation Sperm Tissues
4
Analysis of Phthalate Metabolites in IVF Urine
Cited 8 times
Two urine samples were collected during each IVF cycle (between days 3 and 9 of the gonadotropin phase and on the day of the oocyte retrieval). The median time between the two urine samples collected per cycle was 8 days (interquartile range, 6–9), Urine samples were collected between November 2004 and April 2012. Urine was collected in a sterile polypropylene cup. After measuring specific gravity (SG) using a handheld refractometer (National Instrument Company Inc.), the urine was divided into aliquots and frozen at –80°C. Samples were shipped on dry ice overnight to the CDC (Atlanta, GA) for the quantification of concentrations of MEHP, mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(3-carboxypropyl) phthalate (MCPP), monocarboxyisooctyl phthalate (MCOP), monocarboxyisononyl phthalate (MCNP), monobenzyl phthalate (MBzP), monoethyl phthalate (MEP), mono-isobutyl phthalate (MiBP), and mono-n-butyl phthalate (MBP). The analytical approach, based on solid phase extraction coupled with high performance liquid chromatography-isotope dilution tandem mass spectrometry, followed standard quality assurance/quality control procedures as previously described (Silva et al. 2007 ). The limits of detection (LOD) were 0.5–1.2 μg/L (MEHP), 0.2–0.7 μg/L (MCOP, MEHHP, and MEOHP), 0.2–0.6 μg/L (MECPP and MCNP), 0.1–0.2 μg/L (MCPP), 0.2–0.3 μg/L (MBzP and MiBP), 0.4–0.8 μg/L (MEP), and 0.4–0.6 μg/L (MBP). We calculated the molar sum of DEHP metabolites (ΣDEHP) by dividing each metabolite concentration by its molecular weight and then summing: {[MEHP × (1/278.34)] + [MEHHP × (1/294.34)] + [MEOHP × (1/292.33)] + [MECPP × (1/308.33)]}. MCPP is a metabolite of di-n-octyl phthalate (DnOP) and a nonspecific metabolite of high molecular weight phthalates, MCOP is a metabolite of DiNP, and MCNP is a metabolite of di-isodecyl phthalate (DiDP).
Hauser R., Gaskins A.J., Souter I., Smith K.W., Dodge L.E., Ehrlich S., Meeker J.D., Calafat A.M, & Williams P.L. (2015). Urinary Phthalate Metabolite Concentrations and Reproductive Outcomes among Women Undergoing in Vitro Fertilization: Results from the EARTH Study. Environmental Health Perspectives, 124(6), 831-839.
Publication 2015
2-methyl-5,6-cyclopentapyrimidine di-n-octyl phthalate Diethylhexyl Phthalate diisodecyl phthalate Dry Ice Freezing Gonadotropins High-Performance Liquid Chromatographies Isotopes mecoprop Molar mono(2-ethyl-5-oxohexyl)phthalate mono-(2-ethylhexyl)phthalate mono-isobutyl phthalate monobutyl phthalate monoethyl phthalate Oocyte Retrieval phthalate POLK protein, human Polypropylenes Solid Phase Extraction Sterility, Reproductive Tandem Mass Spectrometry Technique, Dilution Urine
5
IVF Oocyte Retrieval and Monitoring
Cited 7 times
The day 3 FSH concentration was measured with an automated electrochemiluminescence immunoassay using the Elecsys FSH reagent kit and the Roche Elecys 1010/2010 immunoassay analyser (Roche Diagnostics, Indianapolis, IN, USA) at the MGH Core Laboratory. Serum samples to measure oestradiol were collected throughout the monitoring phase of the subject’s IVF treatment cycle. Serum oestradiol was used as a marker of ovarian stimulation and follicular development. The concentration of oestradiol was measured with an automated electrochemiluminescence immunoassay using the Elecsys Estradiol II reagent kit and the Roche Elecys 1010/2010 immunoassay analyser (Roche Diagnostics) at the MGH Core Laboratory. The peak oestradiol concentration was defined as the highest level of oestradiol prior to oocyte retrieval, which was obtained on the day of trigger with hCG.
Oocyte retrieval was performed when follicle sizes on transvaginal ultrasound reached 16–18 mm and the peak oestradiol level reached at least 500 pg/mL. Information on the physician who performed the oocyte retrieval and any complications of the procedure were collected. Retrieved oocytes were cultured in one of two medias: (1) Quinn’s Advantage Fertilization Medium (CooperSurgical Inc., Trumbull, CT, USA) or (2) IVC-TWO (InVitroCare Inc., Frederick, MD, USA). Trained embryologists at the MGH Fertility Center identified the total number of oocytes retrieved per cycle.
Mok-Lin E., Ehrlich S., Williams P.L., Petrozza J., Wright D.L., Calafat A.M., Ye X, & Hauser R. (2009). Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. International journal of andrology, 33(2), 385-393.
Publication 2009
Diagnosis Estradiol Fertility Fertilization Immunoassay Oocyte Retrieval Oocytes Ovarian Follicle Ovarian Stimulation Physicians Precipitating Factors Serum Ultrasonics

Most recents protocols related to «Oocyte Retrieval»

1
Ovarian Stimulation Protocols: A Comparative Evaluation
Ovarian stimulation protocols included gonadotropin-releasing hormone (GnRH) agonist protocol, GnRH antagonist protocol, and progestin-primed ovarian stimulation (PPOS) protocol. Recombinant human chorionic gonadotropin (OVIDREL; Merck Serono, Darmstadt, Germany) or GnRH-a (Decapeptyl; Ferring, Saint-Prex, Switzerland) were administered in patients when two leading follicles reached 18 mm in diameter. Oocyte retrieval was performed at 36 h after recombinant human chorionic gonadotropin or GnRH-a triggered by transvaginal ultrasound-guided aspiration. Insemination method was selected according to the sperm count after sperm preparation. A morphologic score of cleavage-stage embryo was given based on the number of blastomeres, the homogeneous degree of blastomeres, and the degree of cytoplasmic fragmentation, which has been extensively described in our previous study (3 (link)). If a couple has two or more high-quality cleavage-stage embryos on day 3 of embryo culture, the embryos were selected and cultured to blastocyst stage. Blastocyst evaluation was performed according to the Gardner’s grading system (4 (link)).
For patients who underwent GnRH agonist protocol and GnRH antagonist protocol, one to two fresh embryos were transferred into the uterus of women free of OHSS, hydrosalpinx, intrauterine adhesion and high progesterone level (> 1.5 ng/ml) on the day of triggering, and then, the spare embryos were cryopreserved for the next FET. Patients who underwent PPOS protocol had to freeze all their embryos. The vitrified cryopreservation was conducted according to standard protocols, as previously described (5 (link)).
Fan L., Li N., Liu X., Li X., Cai H., Pan D., Wang T., Shi W., Qu P, & Shi J. (2023). Hormone replacement treatment regimen is associated with a higher risk of hypertensive disorders of pregnancy in women undergoing frozen-thawed embryo transfer. Frontiers in Endocrinology, 14, 1133978.
Publication 2023
Blastocyst Blastomeres Cleavage Stage, Ovum Cryopreservation Cytoplasm Decapeptyl Embryo Freezing Gonadorelin Hair Follicle Human Chorionic Gonadotropin Insemination Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovidrel Patients PRIME protocol Progesterone Progestins Sperm Ultrasonography Uterus Woman
2
Oocyte Collection and In Vitro Fertilization
For oocyte collection, 4-week-old naïve C57Bl/6N females were superovulated by intraperitoneal injection of 5 IU pregnant mare serum gonadotropin (Asuka Animal Health, Tokyo, Japan), followed by 5 IU human chorionic gonadotropin (hCG; Mochida Pharmaceutical, Tokyo, Japan) 48 h later. Fifteen hours after hCG injection, the animals were sacrificed and their oviducts removed. The cumulus-oocyte complexes were collected in drops of HTF medium containing approximately 7 × 105 cells/mL sperm from 12-week-old mice from control or VPA groups. In vitro fertilization was performed by co-incubating oocytes with sperm in HTF medium drops for 4 h at 37.5°C in an atmosphere of 5% CO2 in humidified air. After incubation, the oocytes were washed by gentle pipetting in potassium simplex optimized medium [26 (link)] using a glass pipette. The oocytes were transferred to new potassium simplex optimized medium drops and incubated for 72 h at 37.5°C in 5% CO2 in humidified air. After incubation, morphologically normal morular embryos were selected and collected.
Sakai K., Hara K, & Tanemura K. (2023). Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation. PLOS ONE, 18(3), e0282898.
Publication 2023
Animals Atmosphere Embryo Females Fertilization in Vitro Human Chorionic Gonadotropin Morula Mus Oocyte Retrieval Oocytes Oviducts Pharmaceutical Preparations Potassium Pregnant Mare Serum Gonadotropins Sperm
3
Controlled Ovarian Hyperstimulation Protocol for IVF
Controlled ovarian hyper-stimulation was performed using a short-acting GnRH agonist long protocol. Recombinant follicle-stimulating hormone (Merck Serono) was started at least 14 days after the downregulation of GnRH agonist for complete suppression of estradiol from 75 to 300IU/d. Ovulation was induced with human chorionic gonadotropin, and approximately 36 hours later, oocyte retrieval was performed under transvaginal ultrasonographic guidance. Fertilization was carried out using the standard IVF technique; if male infertility or fertilization failure occurred, oocytes were inseminated by ICSI. Embryo transfer was mostly performed using cleaving stage embryos (day 3). If a patient was at risk of ovarian hyperstimulation syndrome, the embryo was vitrified and transferred to a subsequent substituted cycle.
Shen C., Fu W., Fang C., Zhou H, & Wang L. (2023). The impact of weight loss for obese infertile women prior to in vitro fertilization: A retrospective cohort study. Medicine, 102(10), e33009.
Publication 2023
Down-Regulation Embryo Estradiol Fertilization Gonadorelin Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Male Infertility Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovulation Ovum Patients Sperm Injections, Intracytoplasmic Transfers, Embryo
4
Controlled Ovarian Stimulation with GnRH Antagonist
All women underwent controlled ovarian stimulation (COS) with a GnRH antagonist fixed regimen. Bilateral antral follicles (10mm) were counted by transvaginal ultrasonography on the second day of the menstrual cycle, and women started COS treatment with gonadotrophins (Gonal-F, Merck Serono Europe Ltd or Puregon, N. V. Organon). The levels of serum progesterone (SP) were measured using an automated electrochemiluminescence immunoassay (Roche Diagnostics Elecsys Cortisol II assays and COBAS E801), and values were expressed in ng/ml. At our center, the starting dose of gonadotrophins was 150 IU/day for women aged ≤ 34 years, with BMI <24 kg/m2, 6≤AFC<15, and the dosage would be increased if the woman was older (age ≥ 35 years), heavier (BMI ≥ 24 kg/m2), or had poorer ovarian reserve AFC<6 or basal FSH>10 IU/L or AMH <1 ng/ml. Conversely, if the woman is lean (BMI < 19 kg/m2) or has a good ovarian reserve (AFC≥ 15 or AMH≥ 4 ng/ml), the dosage will be reduced. Dose adjustments were determined by the physician based on individual clinical experiences. GnRH antagonists (Cetrorelix, BaxterorGanirelix, N.V.Organon) were given daily starting on day 5 or 6 of stimulation. Human chorionic gonadotrophin (Chorionic Gonadotrophin for Injection, Livzon) was injected once there were at least three follicles >17 mm in diameter or at least two follicles >18 mm in diameter. Oocyte retrieval was performed under ultrasound guidance 34-36 hours after triggering.
Sun X., Yao F., Yin C., Meng M., Lan Y., Yang M., Sun C, & Liu L. (2023). Independent value of PMOI on hCG day in predicting pregnancy outcomes in IVF/ICSI cycles. Frontiers in Endocrinology, 14, 1086998.
Publication 2023
antagonists Biological Assay cetrorelix Diagnosis Gonadorelin Gonadotropins Gonal F Graafian Follicle Hair Follicle Human Chorionic Gonadotropin Hydrocortisone Immunoassay livzon Menstrual Cycle Oocyte Retrieval Ovarian Reserve Ovarian Stimulation Physicians Progesterone Puregon Serum Treatment Protocols Ultrasonography Woman
5
Ovarian Stimulation and IVF Protocols
Conventional agonist or antagonist stimulation protocols were used for ovarian stimulation as previously described (Cai et al., 2017 (link)). The initial and ongoing dosage was determined according to patients’ age, antral follicle count (AFC), BMI, and ovarian response. An intramuscular injection of human chorionic gonadotropin (4000–6000 IU, hCG; Livzen, China) or a subcutaneous injection of recombinant human chorionic gonadotropin (250 μg, Ovidrel, Merck-Serono, Switzerland) was administrated for final triggering when at least one follicle reached a mean diameter of 18 mm. Ovum puncture under transvaginal ultrasound guidance for oocyte retrieval was performed 34–36 h after hCG injection.
Routine IVF protocol in our center was carried out (Jiang et al., 2022 (link)). Cumulus-oocyte complexes were co-cultured with approximate 1.5–3 X 105 progressively motile spermatozoa in pre-equilibrated fertilization culture medium (K-SIFM, Cook) under mineral oil in traditional incubators (C200, Labotect) at 37°C, 6% CO2 and 5% O2 in a humidified atmosphere. After 4 h co-culture, oocytes were denuded and cultured individually in preequilibrated Cleavage Medium (K-SICM, Cook). The culture system and the procedure of semen preparation were kept unchanged in the period of study. Fertilization was determined according to the presence of two pronuclei (2 PN) about 17 h post insemination. It should be confirmed 2 h later if no obvious pronuclei could be observed.
Jiang X., Cai J., Liu L., Liu Z., Chen J., Yang C., Chen K., Yang X., Geng J., Ma C., Lian S., Xu L, & Ren J. (2023). Predicting the unexpected total fertilization failure in conventional in vitro fertilization cycles: What is the role of semen quality?. Frontiers in Cell and Developmental Biology, 11, 1133512.
Publication 2023
Atmosphere Coculture Techniques Cytokinesis Fertilization fibroblast chemotactic inhibitor Graafian Follicle Human Chorionic Gonadotropin Insemination Intramuscular Injection Oil, Mineral Oocyte Retrieval Oocytes Ovarian Follicle Ovarian Stimulation Ovary Ovidrel Ovum Patients Plant Embryos Punctures Sperm Subcutaneous Injections Ultrasonography

Top products related to «Oocyte Retrieval»

1
Gonal f by Merck Group
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
2
Ovitrelle by Merck Group
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
3
Cetrotide by Merck Group
Sourced in Germany, Switzerland, United Kingdom, Spain, France, Netherlands, United States, Japan
Cetrotide is a laboratory product manufactured by Merck Group. It is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. The core function of Cetrotide is to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.
4
Ovidrel by Merck Group
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
5
Menopur by Ferring
Sourced in Switzerland, Germany, United States, Denmark, Canada, Belgium, Spain, China, France, Sweden, United Kingdom
Menopur is a medication used in assisted reproductive technology (ART) procedures. It contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are hormones that play a crucial role in the development and maturation of ovarian follicles.
6
Crinone by Merck Group
Sourced in United Kingdom, Switzerland, Germany
Crinone is a medical device produced by Merck Group that is used for the administration of progesterone in gel form. It is designed to provide a controlled release of progesterone to support early pregnancy in certain medical conditions.
7
Hyaluronidase by Merck Group
Sourced in United States, Germany, Switzerland, United Kingdom, Japan, China, Italy, France, Macao, Israel, Australia, Sao Tome and Principe, Canada, Spain, Netherlands, Czechia
Hyaluronidase is an enzyme used in laboratory settings. It functions by breaking down hyaluronic acid, a component of the extracellular matrix.
8
Cetrorelix by Merck Group
Sourced in Germany, France, Switzerland, Belgium, United Kingdom, Italy, Australia, United States
Cetrorelix is a synthetic peptide that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It acts by blocking the GnRH receptor, thereby inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.
9
Decapeptyl by Ferring
Sourced in Germany, Switzerland
Decapeptyl is a lab equipment product manufactured by Ferring. It is a synthetic peptide that functions as a gonadotropin-releasing hormone (GnRH) agonist.
10
Pregnyl by Organon
Sourced in Netherlands, Australia, Germany, United States
Pregnyl is a laboratory product used for the measurement of human chorionic gonadotropin (hCG) levels. It is a highly purified form of hCG, a naturally occurring hormone produced during pregnancy. Pregnyl can be used as a reference standard or calibrator in assays designed to detect and quantify hCG in biological samples.

More about "Oocyte Retrieval"

Oocyte Retrieval, also known as egg collection or oocyte aspiration, is a critical step in the in vitro fertilization (IVF) process.
This procedure involves the use of ultrasonography to guide a needle through the vaginal wall and into the ovarian follicles, where mature egg cells (oocytes) are aspirated.
The process of Oocyte Retrieval is typically performed using medications like Gonal-F, Ovitrelle, Cetrotide, Ovidrel, Menopur, and Crinone to stimulate the ovaries and promote the development of multiple mature oocytes.
Hyaluronidase may also be used to aid in the extraction of the oocytes.
During the procedure, the patient is often given Cetrorelix, Decapeptyl, or Pregnyl to trigger the final maturation of the oocytes, allowing for their successful retrieval.
Proper technique and optimization of the Oocyte Retrieval protocol are essential for maximizing the yield and quality of the collected oocytes, thereby enhancing the chances of a successful IVF outcome.
The PubCompare.ai platform can help researchers and clinicians identify the most effective Oocyte Retrieval protocols through its advanced natural language processing and comprehensive analysis of published literature, preprints, and patents.
By leveraging this AI-driven platform, you can effortlessly locate and compare protocols to drive scientific breakthroughs and improve reproductive outcomes.